Discover medical breakthroughs and policy insights to stay informed on healthcare trends.
Health
Digital health startup Sword Health has secured a fresh $40 million in funding at a $4 billion valuation, marking a 33% increase from its $3 billion valuation just a year ago. The round was led by returning backer General Catalyst, with participation from Khosla Ventures, Comcast Ventures, and several other
Healthcare
In a bold move to solidify its international presence, Hims & Hers Health announced Tuesday it will acquire Zava, a prominent European telehealth platform. The acquisition marks a pivotal step in the U.S.-based company's strategy to expand beyond domestic borders and tap into growing demand for
Biotechnology
Samsung’s venture capital arm is preparing to invest in California-based medical device startup Exo, as part of a funding round that could reach $100 million. The round is reportedly being led by Sands Capital, Bold Capital, and Qubit Health Capital. Notably, Qubit Health’s chairman, former Medtronic CEO Omar
Biotechnology
Pharmaceutical giant Regeneron announced Monday that it will acquire genetic testing company 23andMe for $256 million, following a court-supervised bankruptcy auction. The deal, if approved, will grant Regeneron ownership of 23andMe’s genomics service and a massive trove of personal and genetic data from roughly 15 million customers. The acquisition
Biotechnology
Biotech startup NewLimit, which is focused on extending healthy human lifespan through cellular reprogramming, has raised a $130 million Series B round led by Kleiner Perkins. The round also included new investors Nat Friedman, Daniel Gross, and Khosla Ventures, along with returning backers like Founders Fund, Dimension Capital, Elad Gil,
Pharmaceutical
Merck is making a $1 billion bet on American manufacturing with plans to build a major production facility in Wilmington, Delaware. The 470,000-square-foot site will be dedicated to producing Keytruda, Merck’s blockbuster cancer immunotherapy drug, for U.S. patients. This marks the company’s first domestic site devoted
Pharmaceutical
Swiss pharmaceutical giant Roche announced a massive $50 billion investment in the United States over the next five years, reinforcing its commitment to the American market amid rising concerns about looming White House tariffs on imported pharmaceutical goods. The investment will generate over 12,000 jobs, with 1,000 directly
Pharmaceutical
In a bold move signaling its deepening commitment to the U.S. market, Swiss pharmaceutical giant Novartis announced plans to invest $23 billion over the next five years to dramatically expand its American footprint. The investment includes the construction of six new manufacturing facilities, expansion of three existing ones, and
Biotechnology
Isomorphic Labs, the artificial intelligence-driven drug discovery startup spun out of DeepMind, has secured $600 million in its first-ever external funding round. The financing, led by Thrive Capital with participation from Alphabet and its venture arm GV, marks a significant milestone for the Alphabet-owned company as it scales its efforts
Biotechnology
Once heralded as a trailblazer in consumer genetics, 23andMe has filed for Chapter 11 bankruptcy protection, marking a dramatic fall from its former $6 billion valuation. The filing was made Sunday night in Missouri federal court, capping off a tumultuous period for the company marked by financial struggles, failed business
Artificial Intelligence (AI)
Reid Hoffman, the billionaire entrepreneur and investor best known for co-founding LinkedIn, is now setting his sights on a new frontier: using artificial intelligence to fight cancer. His latest venture, Manas AI, aims to accelerate drug discovery and improve cancer treatments by merging cutting-edge AI with advanced biomedical research. A
Health
When it comes to maintaining mental sharpness as we age, professional expertise and personal experience both matter. Dr. Richard Restak, a neurology professor at Georgetown University and an author of over 20 books on the mind, offers the best of both worlds. At 83, he combines his deep academic knowledge